MGCLF News and Press, MGC Pharmaceuticals Ltd From 05/10/23

(NewsDirect) MGC Pharmaceuticals chief commercial officer Robert Clements joined Proactive's Stephen Gunnion with details of the company's activity in the first quarter of 2023, as well as upcoming milestones. Clements noted that clinical trials of its CimetrA drug continue to demonst...

2023-04-11 06:39:42 ET MGC Pharmaceuticals ( OTCPK:MGCLF ) said its epilepsy product CannEpil is now available to patients in the U.K. via Named Patient Request. The company noted that CannEpil is an investigational medicinal product (IMP) for patients with refractory ep...

MGC Pharma's CannEpil® Now Accessible to UK Patients on Named Patient Request Basis PR Newswire European pharmaceutical company offers its investigational medicinal product to a wide range of specialist medical practitioners in the United Kingdom Epidiolex's S...

(NewsDirect) MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive after announcing that the company has been granted permission by the Slovenian government to conduct research into psilocybin, a naturally occurring psychedelic ...

(NewsDirect) MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive's Thomas Warner after announcing the enrolment of the first patient in its proprietary data collection App and machine learning algorithm, ZAM. Clements expl...

ArtemiC TM Listed as an OTC Drug in the USA; AMC Places US$2m Order PR Newswire Innovative Plant-Based Medicine Set to Transform Inflammatory Disease Treatments in the US Market LONDON , March 22, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX...

(NewsDirect) MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief medical officer Nadya Lisovoder speaks to Proactive's Thomas Warner after announcing the completion of an in-vitro pre-clinical mechanism of action (MoA) study for the European based bio-pharma company's CimetrA plat...

(NewsDirect) MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive's Thomas Warner about how the business performed during the fourth quarter of 2022. Clements says that the "numbers were very good" and reveals more details about ho...

MGC Pharmaceuticals (OTCPK:MGCLF) signed an exclusive distribution agreement with Sciensus Rare for distributing phytocannabinoid derived products — CannEpil to treat drug resistant epilepsy and CogniCann for Dementia and Alzheimer's disease — in certain European terri...

MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK PR Newswire LONDON , April 5, 2022 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC, A...